Verona Pharma PLC ADR (VRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verona Pharma PLC ADR (VRNA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.56 Million) by net assets ($278.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Verona Pharma PLC ADR for the company's overall valuation and market capitalisation.
Verona Pharma PLC ADR - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Verona Pharma PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Verona Pharma PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma PLC ADR ranked by their cash flow conversion efficiency. Explore Verona Pharma PLC ADR cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canadian Utilities Limited
TO:CU
|
0.060x |
|
Hangzhou Silan Microelectronics Co Ltd
SHG:600460
|
0.066x |
|
Anji Microelectronics Tech Co Ltd
SHG:688019
|
0.004x |
|
Andritz AG
VI:ANDR
|
0.044x |
|
BARRY CALLEBA. ADR 1/100
F:BCLM
|
N/A |
|
Unigroup Guoxin Microelectronics Co Ltd
SHE:002049
|
-0.011x |
|
Clearwater Analytics Holdings Inc
NYSE:CWAN
|
0.009x |
|
VinFast Auto Ltd. Ordinary Shares
NASDAQ:VFS
|
0.134x |
Annual Cash Flow Conversion Efficiency for Verona Pharma PLC ADR (2005–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma PLC ADR from 2005 to 2024. View Verona Pharma PLC ADR share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $204.56 Million | $-122.20 Million | -0.597x | -196.53% |
| 2023-12-31 | $249.28 Million | $-50.22 Million | -0.201x | +22.44% |
| 2022-12-31 | $230.47 Million | $-59.86 Million | -0.260x | -15.61% |
| 2021-12-31 | $148.00 Million | $-33.25 Million | -0.225x | +7.86% |
| 2020-12-31 | $184.85 Million | $-45.08 Million | -0.244x | +75.58% |
| 2019-12-31 | $44.40 Million | $-44.34 Million | -0.999x | -247.03% |
| 2018-12-31 | $79.86 Million | $-22.98 Million | -0.288x | -11.07% |
| 2017-12-31 | $107.95 Million | $-27.97 Million | -0.259x | -59.81% |
| 2016-12-31 | $42.53 Million | $-6.89 Million | -0.162x | +85.74% |
| 2015-12-31 | $8.28 Million | $-9.41 Million | -1.137x | -304.82% |
| 2014-12-31 | $19.62 Million | $-5.51 Million | -0.281x | +71.73% |
| 2013-12-31 | $3.41 Million | $-3.39 Million | -0.993x | -2.41% |
| 2012-12-31 | $4.21 Million | $-4.08 Million | -0.970x | -149.67% |
| 2011-12-31 | $6.29 Million | $-2.44 Million | -0.389x | +19.22% |
| 2010-12-31 | $5.33 Million | $-2.56 Million | -0.481x | -33.08% |
| 2009-12-31 | $7.25 Million | $-2.62 Million | -0.361x | -6.93% |
| 2008-12-31 | $5.85 Million | $-1.98 Million | -0.338x | +18.99% |
| 2007-12-31 | $5.73 Million | $-2.39 Million | -0.417x | -363.37% |
| 2006-12-31 | $7.64 Million | $-687.68K | -0.090x | -4507.76% |
| 2005-12-31 | $1.68 Million | $3.44K | 0.002x | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more